NeuroCare – Risk Panel
NeuroCare comprehensive risk panel is a suite of neurodegenerative and neuroinflammatory biomarker tests designed to assess an individual’s risk of developing various neurological disorders. This panel evaluates biomarkers associated with the progression of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis.
Components of the NeuroCare Risk Panel:
- Amyloid-β 42 (Aβ42): Measures the levels of amyloid-β 42 in the cerebrospinal fluid (CSF), which is closely associated with the development of Alzheimer’s disease.
- Total Tau (t-Tau): Assesses the levels of total tau protein, a biomarker of neurodegeneration commonly elevated in Alzheimer’s disease and other neurodegenerative disorders.
- Phosphorylated Tau (p-Tau): Evaluates the levels of phosphorylated tau protein, indicating tau pathology and neurodegeneration.
- Alpha-Synuclein (α-Synuclein): Measures the levels of alpha-synuclein, a protein associated with the development of Parkinson’s disease and other synucleinopathies.
- Neopterin: Assesses the levels of neopterin, a marker of neuroinflammation and potentially indicative of conditions such as multiple sclerosis.
- N-Fold Cross-Sectional Association (NFCSA): Evaluates the levels of NFCSA, a biomarker associated with neuroinflammation and potentially indicative of conditions such as multiple sclerosis.
- S100B: Assesses the levels of S100B protein, a marker of neurodegeneration and potentially indicative of conditions such as Alzheimer’s disease and Parkinson’s disease.
Benefits of the Risk Panel:
- Early Detection: Identifies individuals at risk of developing neurodegenerative diseases, enabling early interventions and potentially slowing disease progression.
- Personalized Medicine: Allows for tailored treatment plans based on individual biomarker profiles, enhancing treatment efficacy and patient outcomes.
- Risk Stratification: Helps healthcare providers assess an individual’s likelihood of developing specific neurodegenerative diseases, guiding clinical decisions and resource allocation.
- Family Planning and Genetic Counseling: Provides valuable information for individuals and families considering genetic testing or family planning options related to neurodegenerative diseases.
- Advancing Research and Understanding: Contributes to the development of new biomarkers and therapeutic targets, driving progress in the field of neurodegenerative diseases.
Understand Your Risks Today with Our NeuroCare Risk Panel
Take the first step towards a healthier brain. Click here to assess your neuro risk factors and personalize your care plan.